JPMorgan Chase & Co. Issues Positive Forecast for Guardant Health (NASDAQ:GH) Stock Price

Guardant Health (NASDAQ:GH) had its price objective lifted by equities researchers at JPMorgan Chase & Co. from $48.00 to $50.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 74.76% from the company’s current price.

A number of other analysts have also recently commented on the company. UBS Group upped their price target on Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, August 21st. Leerink Partners reduced their price target on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Bank of America upped their price objective on shares of Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, July 18th. Craig Hallum raised their price objective on Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Finally, BTIG Research boosted their target price on Guardant Health from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $39.75.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $28.61 on Thursday. Guardant Health has a 52 week low of $15.81 and a 52 week high of $37.04. The company has a current ratio of 6.40, a quick ratio of 6.07 and a debt-to-equity ratio of 16.70. The firm has a fifty day moving average of $23.13 and a two-hundred day moving average of $25.98.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 660.24%. The company had revenue of $177.24 million during the quarter, compared to the consensus estimate of $162.59 million. During the same quarter in the prior year, the company posted ($0.67) EPS. The company’s revenue for the quarter was up 29.2% compared to the same quarter last year. As a group, equities research analysts forecast that Guardant Health will post -3.31 earnings per share for the current year.

Institutional Trading of Guardant Health

A number of institutional investors have recently made changes to their positions in the business. JNBA Financial Advisors acquired a new stake in shares of Guardant Health in the third quarter valued at about $26,000. Ashton Thomas Securities LLC acquired a new position in shares of Guardant Health during the 3rd quarter worth approximately $34,000. Quarry LP bought a new stake in shares of Guardant Health during the 2nd quarter worth approximately $44,000. Manchester Capital Management LLC acquired a new stake in shares of Guardant Health in the 1st quarter valued at approximately $57,000. Finally, Canton Hathaway LLC bought a new position in shares of Guardant Health in the second quarter valued at $59,000. Institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.